Takada eyeing potential Shire asset sales to pay down debt

13th Sep 2018 10:56

(Sharecast News) - Takeda Pharmaceutical may try and sell Shire's dry-eye drug once it completes the $62bn takeover purchase of the UK-listed biotech, according to a report on Thursday. Shire's Xiidra drug is among various potential divestments being mulled by Takeda, according to a report from Bloomberg, with Takeda also looking at selling the Dublin-headquartered group's Natpara treatment for low blood calcium.Takeda wants to raise cash so it can trim the huge levels of debt it is raising to fund the deal.